Pharma Focus Asia
Eppendorf Bioprocess Solutions

Genentech Developed Breakthrough Therapy Gantenerumab for Alzheimer’s Disease

Genentech developed a breakthrough therapy for the treatment of patients living with early Alzheimer's disease (AD). This will be the first medicine to treat Alzheimer’s disease at-home administration.

Gantenerumab is the first investigational IgG1 antibody designed with late-stage trials for the treatment of AD. It binds the aggregated forms of amyloid beta and removes brain amyloid plaques, a pathological hallmark of Alzheimer’s disease (AD).

The pivotal GRADUATE trials carried out for gantenerumab will investigate its effects on amyloid load and downstream biomarkers of disease as well as safety and efficiency of gantenerumab early (prodromal-to-mild) AD in patients.

Alzheimer's disease (AD) is a type of brain disorder causing weaking in memory, language and other problems such as thinking skills, changes in mood and behaviour. Alzheimer's the common form of dementia and it is expected to reach disease population of 78 million by 2030 and currently affecting more than 55 million people globally. Moreover, nearly 10 million people are diagnosed with AD every year.

U.S. Food and Drug administrator has granted breakthrough therapy designation for Gantenerumab, investigational antibody for Alzheimer's disease (AD).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEAMasterControl - Simplify CAPA in 7 StepsTFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile App3rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023CPHI & PMEC China 2023Pharma Regulatory Conclave 2023Thermo Fisher Scientific - QualTrak